		Technical Data
E3373-09F	EphB6, NT (S45) (Ephrin Type-A Receptor 6, Tyrosine-protein Kinase Receptor EPH-6, HEP)

Description:
Ephrin receptors and their ligands, the ephrins, mediate numerous developmental processes, particularly in the nervous system. Based on their structures and sequence relationships, ephrins are divided into the ephrin-A (EFNA) class, which are anchored to the membrane by a glycosylphosphatidylinositol linkage, and the ephrin-B (EFNB) class, which are transmembrane proteins. The Eph family of receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. Ephrin receptors make up the largest subgroup of the receptor tyrosine kinase (RTK) family. EphB6 lacks the kinase activity of most receptor tyrosine kinases and binds to ephrin-B ligands.

Applications:
Suitable for use in ELISA, Western Blot, Flow Cytometry, and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Western Blot: 1:100-1:500
ELISA: 1:1,000
Immunohistochemistry: 1:50-1:100
Flow Cytometry: 1:10-1:50
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Type	Isotype	Clone	Grade
Pab	IgG		Affinity Purified

Size		Storage	Shipping	Source	Host
100ug		-20°C	Blue Ice	Human	Rabbit

Concentration:

~0.25mg/ml

Immunogen:

Synthetic peptide selected from N-terminal region with serine at position 45 of human EphB6 (KLH).

Purity:

Purified by Protein G affinity chromatography.

Form

Supplied as a liquid in PBS, 0.09% sodium azide.

Specificity:

Recognizes human EphB6.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.

1.Freywald, A., et al., J. Biol. Chem. 278(12):10150-10156 (2003). 2.Luo, H., et al., J. Clin. Invest. 110(8):1141-1150 (2002). 3.Wilkinson, D.G., Nat Rev Neurosci 2(3):155-164 (2001). 4.Luo, H., et al., J. Immunol. 167(3):1362-1370 (2001). 5.Tang, X.X., et al., Proc. Natl. Acad. Sci. USA 97(20):10936-10941 (2000). 6.Jun Yu, et al. Clin. Cancer Res., Apr 2010; 16: 2275-2283.(E-pub)